Even greater expectations are traditionally associated with ‘pharmacological’ inhibition of HSP70 in breast cancer cells, i.e., when the expression level or cancer-promoting activities of this chaperone would somehow be suppressed by a drug or natural compound. This evidence concerns the gene HSPA1A and breast cancer.